Startseite/Aktien/STTK

STTK

USD

Shattuck Labs Inc. Common Stock

$1.930-0.030 (-1.531%)

Echtzeitkurs

Healthcare

Biotechnologie

Vereinigte Staaten

Kursdiagramm

Loading Chart...

Schlüsselkennzahlen

Marktkennzahlen

Unternehmensfundamentaldaten

Handelsstatistiken

Marktkennzahlen

Eröffnung

$1.960

Hoch

$2.075

Tief

$1.858

Volumen

0.10M

Unternehmensfundamentaldaten

Marktkapitalisierung

92.5M

Branche

Biotechnologie

Land

United States

Handelsstatistiken

Durchschnittliches Volumen

0.81M

Börse

NMS

Währung

USD

52-Wochen-Spanne

Tief $0.692Aktuell $1.930Hoch $2.705

Ähnliche Nachrichten

8. Sept. 2025 · 13:07

Analyst Upgrades

Wedbush Initiates Coverage On Shattuck Labs with Outperform Rating, Announces Price Target of $4

Wedbush analyst David Nierengarten initiates coverage on Shattuck Labs with a Outperform rating and announces Price Target of $4.

Wedbush Initiates Coverage On Shattuck Labs with Outperform Rating, Announces Price Target of $4

26. Aug. 2025 · 10:30

GlobeNewswire

Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors

— Aggregate net proceeds from private placement expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease — — Pro forma

Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors

21. Aug. 2025 · 14:17

GlobeNewswire

Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease

– SL-325 is a potentially first-in-class DR3 antagonist antibody being developed for the treatment of Inflammatory Bowel Disease (IBD) and other inflammatory and immune-mediated diseases – – The Company is on track to